Moleculin Biotech Operating Income

Moleculin Biotech (MBRX) currently reports a operating income of $-29M as of June 2026. That compares with $-25M in the prior-year period — down 13.5% year over year. Use the charts on this page to explore Moleculin Biotech's operating income history and peer comparisons.

Moleculin Biotech's operating income decreased from $-25M to $-29M — a 13.5% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Moleculin Biotech reported $-29M in operating income as of June 2026. That compares with $-25M in the prior-year period — down 13.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-29M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Moleculin Biotech, and consider following MBRX for alerts when major investors trade the stock.

Moleculin Biotech is classified in the Healthcare sector. On operating income, it currently shows $-29M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MBRX with unrelated industries.